Aplastic Anemia https://greenmedinfo.com/taxonomy/term/784/all en Allopurinol induced aplastic anemia in a patient with chronic renal failure. https://greenmedinfo.com/article/allopurinol-induced-aplastic-anemia-patient-chronic-renal-failure PMID:  Ryumachi. 1990 Aug ;30(4):281-6. PMID: 2287969 Abstract Title:  [Allopurinol induced aplastic anemia in a patient with chronic renal failure]. Abstract:  A 43 year old female patient with chronic renal failure originated from polycystic kidney disease was admitted with pancytopenia. Prior to the admission, she had a history of taking allopurinol for 3 months. Allopurinol was discontinued immediately and she was treated with blood transfusion (platelet and RBC) and fluoxymesterone. The lymphocyte stimulation tests were negative for allopurinol and oxipurinol. The determination of serum levels of allopurinol and oxipurinol was disclosed to be not so high compared with other patients treated with allopurinol. On 45th day after admission, she was transfused with bone marrow from her elder brother. Thereafter bone marrow finding of the patient began to improve despite the lack of bone marrow engraftment. For further improvement, pulse treatment with corticosteroid was carried out. Although the pathophysiology of allopurinol-induced aplastic anemia remains unknown, it is interesting to note that bone marrow transfusion and pulse treatment with corticosteroid seemed effective in this case. https://greenmedinfo.com/article/allopurinol-induced-aplastic-anemia-patient-chronic-renal-failure#comments Aplastic Anemia Kidney Failure: Chronic Allopurinol Human: Case Report Sun, 21 Oct 2012 23:19:55 +0000 greenmedinfo 83344 at https://greenmedinfo.com Rehmannia appears to be effective than the drug stanozolol in accelerating symptom remission in patients with Chronic Aplastic Anemia. https://greenmedinfo.com/article/rehmannia-appears-be-effective-drug-stanozolol-accelerating-symptom-remission- PMID:  Ugeskr Laeger. 2009 Dec 7;171(50):3690-3. PMID: 11477910 Abstract Title:  [Treatment of 34 cases of chronic aplastic anemia using prepared Rehmannia polysaccharide associated with stanozolol]. Abstract:  OBJECTIVE: To investigate the effect and side effect of prepared Rehmannia polysaccharide (PRP) associated with stanozolol in treating chronic aplastic anemia (CAA). METHODS: Thirty-four cases of CAA were treated by PRP liquid associated with stanozolol, course of 3 week treatment, and control group (17 cases of CAA) was treated by stanozolol alone. RESULTS: Effective rate was 85.3% in treatment group, and that of control group was 58.8%, there was significant difference between them (P < 0.05). Symptom remission of treatment group was earlier than that of control group, symptom scoring between two groups, the difference was highly significant (P < 0.01). Blood cell had a distinct elevation after treatment with PRP associated with stanozolol, and had a significant difference in comparing with pre-treatment in treatment group (P < 0.01). Side effect of PRP was not found during treatment of CAA. CONCLUSIONS: PRP associated with stanozolol to treat CAA has an additional effect, it can accelerate symptom remission without any additional side effect.   https://greenmedinfo.com/article/rehmannia-appears-be-effective-drug-stanozolol-accelerating-symptom-remission-#comments Aplastic Anemia Rehmannia Superiority of Natural Substances versus Drugs Human Study Thu, 10 Dec 2009 15:21:51 +0000 greenmedinfo 48230 at https://greenmedinfo.com